EZH2 and triple-A syndrome: Overexpression of EZH2 can increase the level of ANXA6 promoter H3K27me3, reduce the expression of ANXA6, inhibit the increase in ROS induced through Ang II and the senescence of VSMCs, and alleviate the pathogenesis of AAA.